New Data Showing that Transgene and NEC's Individualized Can

New Phase I data confirm promising immunogenicity and efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation In the head

Related Keywords

France , United States , Paris , France General , Florida , United Kingdom , Ankara , Turkey , Institut Curie , Alexandra Martinez , Lucie Larguier , Ben Brahim , Sylvie Berrebi , Meetingin Orlando , Yujie Zhao , Transgene Euronext , Christian Ottensmeier , Le Tourneau , Christophe Le Tourneau , Masamitsu Kitase , Jean Pierre Delord , Healthcare Life Sciences Business , Nec Ai Drug Development Business , American Association For Cancer Research , Head Of The Department Drug Development , Head Of Surgical Department , Ai Drug Development Division , Jolla Institute For Immunology , University Of Liverpool , Astrazeneca , Twitter , Corporate Communications , Clatterbridge Cancer Centre , Euronext Paris , American Association , Cancer Research , Annual Meetingin Orlando , Corporate Senior , Managing Director , Serious Adverse Events , Consultant Medical Oncologist , Drug Development , Consultant Medical Oncology , Consultant Immunology , Associate Professor , Mayo Clinic , Associate Head , Surgical Department , Vaccinia Ankara , Artificial Intelligence , Prediction System , Development Business , Risk Factors , Universal Registration Document , Data , Showing , Transgene , Individualized , Dancer , Vaccine , G4050 , Induces , Strong , Specific , Immune , Responses , Against , Rumors , Resented , Racr , 023 ,